Life Sciences

Greg Kupp – President Life Sciences Division & Frank Tagliaferri – VP of Technical DevelopmentPace® Life Sciences were recently interviewed by Investment Reports. Read the full inter view here.

Pace ® is happy to share news from our client, ReveraGen BioPharma Inc., on a significant accomplishment! ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy. Pace® Ann Arbor (legacy Velesco Pharmaceutical Services) contributed significantly to this success. Velesco Pharma (now Pace®) performed the drug product clinical formulation development and all drug

First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule

Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried

Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve commercial compliance in FDA-regulated environments. Minneapolis, MN, August 18, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace® Science and Technology Company, announced today that it